MAIT cells with their increased expression of PD-1, CTLA-4 and TIM-3 in cancer may be targets for immune-checkpoint inhibitor therapy, potentially restoring MAIT cells anti-tumour abilities. This evidence concerns the gene HAVCR2 and neoplasm.